D&D Pharmatech advances Phase 2 candidates
South Korean biopharmaceutical company D&D Pharmatech demonstrated a 62.5% resolution rate for metabolic dysfunction-associated steatohepatitis (MASH) with its new drug.
- Field
- drugs and trials
- What they did
- D&D Pharmatech developed a liver drug that resolved MASH (metabolic dysfunction-associated steatohepatitis) in 62.5% of patients.
- Why it matters
- This could be useful for patients with chronic metabolic diseases, as the drug is taken orally and aims to improve their condition.
#mash#biopharmaceutical#clinical trial



